Summary
The U.S. commercial weight loss market, a $384 billion industry, is undergoing significant change due to the rise of GLP-1 drugs, or glucagon-like peptide-1 receptor agonists. Initially developed to manage type 2 diabetes, these drugs have been increasingly adopted for their weight-loss effects and potential in obesity management. The increasing popularity of GLP-1 drugs such as exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide is having far-reaching impacts, with potential consequences for the food and beverage industry, consumer behavior, and healthcare practices.
GLP-1 drugs function by lowering serum glucose levels to manage metabolism and have shown to result in weight loss, a phenomenon linked to the satiety effect of GLP-1 agonists. Certain GLP-1 drugs, such as semaglutide and liraglutide, have proven to be more effective than others in clinical trials. While these drugs come with potential side effects, their adoption is reshaping the weight loss market and influencing consumer habits, with impacts on sectors such as food manufacturing and retail.
The introduction of GLP-1 drugs in the market is posing new challenges and opportunities for commercial diet companies, manufacturers, and healthcare providers. The traditional weight loss services sector has been experiencing a decline, with the job loss of an estimated 26,500 weight loss coaches since 2020. However, the increased use of GLP-1 drugs, combined with an increase in bariatric surgeries, indicates potential areas of growth in the market.
Predictions for the future of the U.S. commercial weight loss market suggest an ongoing shift in dynamics, driven by the adoption of GLP-1 drugs and health-conscious consumer behaviors. With financial analysts estimating the market for GLP-1 drugs to exceed $100 billion by the 2030s, the industry is set to navigate significant changes, requiring adaptation and innovation from market players.
Understanding GLP-1 Drugs
GLP-1 drugs, also known as GLP-1 agonists or glucagon-like peptide-1 receptor agonists, have been utilized for the treatment of type 2 diabetes and obesity. These drugs are part of the incretin mimetics drug class and function by lowering serum glucose levels to manage metabolism in affected patients. GLP-1 receptor agonists include exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and others, administered daily or weekly depending on the specific drug.
Initially, GLP-1RAs were manufactured as an injectable medication due to their poor oral bioavailability. Exenatide and lixisenatides are primarily eliminated by the kidneys, while liraglutide, dulaglutide, albiglutide, and semaglutide are metabolized similarly to large proteins, without a specific organ as the primary route of elimination.
GLP-1 Drugs’ Effect on Glucose and Weight
Apart from the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective effects. Unlike GIP, the action of GLP-1 is preserved in patients with type 2 diabetes. These combined effects often result in weight loss, a phenomenon linked to the satiety effect of GLP1-agonists that reduces food intake, appetite, and hunger. The role of GLP-1 drugs in weight management has become increasingly prominent, and their growing usage could potentially affect growth in traditional food categories, particularly snack foods.
Efficacy of Different GLP-1 Drugs
Certain GLP-1 drugs have proven to be more effective than others in clinical trials. For example, semaglutide, the active ingredient in Ozempic and Wegovy, was associated with greater reductions in glycated hemoglobin and body weight compared to dulaglutide, exenatide extended-release (ER), liraglutide, and lixisenatide. Similarly, liraglutide has demonstrated more significant reductions in body weight compared to short- and long-acting exenatide, short-acting lixisenatide, and long-acting dulaglutide.
Side Effects of GLP-1 Drugs
While effective, GLP-1 drugs do come with potential side effects. Commonly reported adverse effects include nausea, vomiting, fatigue, diarrhea, constipation, and skin changes like “Ozempic face,” where the skin on the face sags and wrinkles. These side effects often lead patients to gradually adjust their dosage to a level that minimizes discomfort.
The Future of GLP-1 Drugs
The approval of exenatide by the U.S. Food and Drug Administration in 2005 marked a significant turning point for the pharmaceutical industry’s interest in targeting the GLP-1 receptor, inspiring further research and development in this area. With the efficacy of these drugs in reducing body weight, formulations like once-daily liraglutide and once-weekly semaglutide are being further investigated for obesity management. As the market for GLP-1RA drugs continues to evolve, manufacturers, retailers, and clinicians will need to adapt their strategies to align with these changes.
The U.S. Commercial Weight Loss Market
The U.S. Commercial Weight Loss Market has undergone significant changes in recent years. An estimated 26,500 weight loss coaches lost their jobs since 2020, mainly due to layoffs by commercial diet companies. This trend has impacted the quality and nature of support available to dieters. The market size of the Weight Loss Services in the US has declined at a -2.9% Compound Annual Growth Rate (CAGR) between 2019 and 2024. Most non-medical segments of the market have experienced declining sales. However, the weight loss industry is seeing more physicians adding weight loss to their practices, and an increase in bariatric surgeries. Also, medical weight loss franchises and bariatricians are witnessing growth in their caseloads and revenues.
The obesity drugs market, particularly GLP-1 agonists, originally developed to treat diabetes, is one aspect of the industry that is experiencing significant growth. Forecasts suggest the GLP-1 market will exceed $100 bn by 2030, fuelled equally by diabetes and obesity usage. It is estimated that the total GLP-1 users in the U.S. may number 30 million by 2030 — or around 9% of the overall population.
The adoption of GLP-1 drugs is impacting consumer behavior and creating a paradigm shift in health care. An in-depth consumer study of approximately 3,000 people shows that these medications are influencing lifestyles, spending habits, and consumption patterns. This trend is reshaping the food and beverage industry, offering opportunities for innovation and business model reinvention. The integration of Internet of Things (IoT) and wearable technologies is influencing companies to integrate these advancements in product development and marketing strategies.
In 2023, Semaglutide, a GLP-1 drug, became the best-selling drug in the United States with $13.8 billion in sales. The market for these therapies, which includes over 100 million obese adults eligible for weight loss drug therapy, is rapidly expanding. Adoption of GLP-1 drugs is also anticipated to grow dramatically, especially as the medical and institutional community begin to recommend GLP-1s as the standard of care for treating obesity.
This change in the weight loss market warrants new thinking and new approaches by producers. Food manufacturers, for example, are advised to adapt by adjusting their food ingredients and packaging. GLP-1 drugs and their impact on consumer habits are providing invaluable information for industry players. Manufacturers and retailers are encouraged to assess their current product portfolios and manage their future strategies to adapt to these changing market dynamics.
Impact of GLP-1 Drugs on Bariatric Surgery Outcomes
Bariatric surgery has been recognized as a viable treatment option for obesity, a chronic biological disease. This recognition has led to a steady increase in the number of these procedures being performed. According to the American Society for Metabolic and Bariatric Surgery, the volume of bariatric surgeries has increased from 158,000 in 2011 to 280,000 in 2022.
Despite the increasing volume of procedures, a significant proportion of patients do not achieve their metabolic and weight loss goals after bariatric surgery. About 1 in 4 people do not experience significant weight loss following the procedure. However, recent research indicates that the use of glucagon-like peptide-1 (GLP-1) receptor antagonist drugs may improve outcomes for these patients.
Two new studies have shed light on the impact of GLP-1 drugs on bariatric surgery outcomes. These drugs, used preoperatively, may enhance weight loss and metabolic outcomes in individuals who did not meet their goals within a year following bariatric surgery. This potential benefit is especially pertinent given the cost associated with newer weight loss drugs.
Future Predictions for the U.S. Commercial Weight Loss Market
Despite the decline in the market and loss of jobs, the integration of more physicians adding weight loss to their practices and an increase in bariatric surgeries suggest a potential area of growth. Furthermore, the impact of GLP-1 drugs on consumer habits, such as decreased alcohol consumption among users, could also influence related sectors, offering new opportunities for businesses to adapt and thrive.
In light of these developments, the U.S. commercial weight loss market is set to navigate through significant changes, offering both challenges and opportunities. The market players will need to evaluate their current strategies and adapt to the evolving market dynamics to ensure future success.
The content is provided by Blake Sterling, Brick By Brick News
